{
    "persona": "conservative",
    "model": "llama2:70b-chat-q6_K",
    "topic": "healthcare",
    "language": "German",
    "text": "@Ashina Report: Congrats on the promising long-term data for Atogepant in migraine prevention! 70% of patients achieved 50% reduction in monthly migraine days at weeks 13-16, sustained over 48 weeks. Mean duration of exposure was 496.5 days, mean baseline migraine days were 14.5. Atogepant improved monthly migraine days by 8.5 days on average. Exciting news for patients and clinicians!",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "5c8404bd69575d77a3de5e0a515349c0cb0539f85061e7c3"
}